Jakavi 20 — Ruxolitinib 20 mg (56 Tablets)
Jakavi (Ruxolitinib) is a highly effective antineoplastic drug that acts as a selective inhibitor of Janus kinases (JAK1 and JAK2). These enzymes play a key role in the processes of hematopoiesis and immune response. In several myeloproliferative diseases, hyperactivity of the JAK pathways leads to uncontrolled blood cell division and the development of severe complications. Jakavi specifically blocks these signaling pathways, contributing to a reduction in spleen size and significant relief of disease symptoms.
Manufacturer: Novartis. Jakavi is the world's first drug approved for the targeted therapy of myelofibrosis, providing a significant improvement in patient survival and quality of life.
Key Features:
- ✅ Splenomegaly Control: Proven efficacy in reducing an enlarged spleen.
- ✅ Symptom Improvement: Effectively eliminates night sweats, skin itching, bone pain, and chronic fatigue.
- ✅ Targeted Therapy: Acts directly on the pathogenetic mechanism of the disease (JAK-STAT pathway).
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 21.04.2026
Similar products
What Customers Say
No reviews yet
Your review can be the first!